Agency Information Collection Activities; Proposed Collection; Comment Request; Substances Prohibited from Use in Animal Food or Feed; Animal Proteins Prohibited in Ruminant Feed, 70409-70410 [E6-20476]
Download as PDF
70409
Federal Register / Vol. 71, No. 232 / Monday, December 4, 2006 / Notices
ANNUAL BURDEN ESTIMATES—Continued
Number of
respondents
Instrument
Child Assessment ...................................................................................
Teacher Survey/TCR ..............................................................................
Principal Survey ......................................................................................
Year 2 (fall 2007):
Parent Tracking Interview .......................................................................
Year 2 (spring 2008):
Parent Tracking Interview .......................................................................
Parent Interview ......................................................................................
Child Assessment ...................................................................................
Teacher Survey/TCR ..............................................................................
Principal ..................................................................................................
Estimated Total Annual Burden
Hours: 6,484
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Information Services, 370 L’Enfant
Promenade, SW., Washington, DC
20447, Attn: ACF Reports Clearance
Officer. E-mail address:
infocollection@ach.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, 725 17th Street, NW.,
Washington, DC 20503, E-mail address:
Karen_T._Matsuoka@omb.eop.gov, Attn:
Desk Officer for ACF.
Dated: November 28, 2006.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 06–9504 Filed 12–1–06; 8:45 am]
BILLING CODE 4184–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
mstockstill on PROD1PC61 with NOTICES
[Docket No. 2006N–0472]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Substances
Prohibited from Use in Animal Food or
Feed; Animal Proteins Prohibited in
Ruminant Feed
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Aug<31>2005
11:51 Dec 01, 2006
Jkt 211001
Number of responses per
respondent
Frm 00050
Fmt 4703
Sfmt 4703
Total burden
hours
1,720
2,580
1,462
1
1
1
1.00
0.50
0.33
4,667
1
0.166
778
2,108
2,042
2,042
3,063
1,736
1
1
1
1
1
0.166
1.00
1.00
0.50
0.33
351
2,042
2,042
1,532
579
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
extending OMB approval on the existing
recordkeeping requirements for this
information collection, regarding animal
proteins prohibited in ruminant feed.
DATES: Submit written or electronic
comments on the collection of
information by February 2, 2007.
ADDRESSES: Submit electronic
comments on the collection of
information to: https://www.fda.gov/
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1472.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
PO 00000
Average burden
hours per
response
1,720
1,290
487
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Substances Prohibited From Use in
Animal Food or Feed; Animal Proteins
Prohibited in Ruminant Feed—21 CFR
589.2000(e)(1)(iv) (OMB Control
Number 0910–0339)—Extension
This information collection was
established because epidemiological
evidence gathered in the United
Kingdom suggested that bovine
spongiform encephalopathy (BSE), a
progressively degenerative central
nervous system disease, is spread to
ruminant animals by feeding protein
derived from ruminants infected with
BSE. This regulation places general
requirements on persons that
manufacture, blend, process, and
E:\FR\FM\04DEN1.SGM
04DEN1
70410
Federal Register / Vol. 71, No. 232 / Monday, December 4, 2006 / Notices
distribute products that contain or may
contain protein derived from
mammalian tissue, and feeds made from
such products.
The respondents for this collection of
information are manufacturers and or
distributors of products that contain or
may contain protein derived from
mammalian tissues and feeds made
from such products.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
21 CFR Section
589.2000 (e)(1)(iv)
1There
400
BILLING CODE 4160–01–S
1
Hours per
Record
400
Food and Drug Administration
[Docket No. 2006N–0475]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Human Tissue
Intended for Transplantation
AGENCY:
Food and Drug Administration,
HHS.
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection requirements
relating to FDA regulations for human
tissue intended for transplantation.
DATES: Submit written or electronic
comments on the collection of
information by February 2, 2007.
ADDRESSES: Submit electronic
comments on the collection of
information to: https://www.fda.gov/
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
VerDate Aug<31>2005
11:51 Dec 01, 2006
Jkt 211001
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4659.
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on PROD1PC61 with NOTICES
Total Annual
Records
Total Hours
14
5,600
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: November 28, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy
[FR Doc. E6–20476 Filed 12–01–06; 8:45 am]
ACTION:
Annual Frequency
per Recordkeeping
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Human Tissue Intended for
Transplantation—21 CFR Part 1270
(OMB Control Number 0910–0302)—
Extension
Under section 361 of the Public
Health Service (PHS) Act (42 U.S.C.
264), FDA issued regulations to prevent
the transmission of human
immunodeficiency virus (HIV), hepatitis
B, and hepatitis C, through the use of
human tissue for transplantation. The
regulations provide for inspection by
FDA of persons and tissue
establishments engaged in the recovery,
screening, testing, processing, storage,
or distribution of human tissue. These
facilities are required to meet provisions
intended to ensure appropriate
screening and testing of human tissue
donors and to ensure that records are
kept documenting that the appropriate
screening and testing have been
completed.
Sections 1270.31(a) through (d) (21
CFR 1270.31(a) through (d)) require
written procedures to be prepared and
followed for the following steps: (1) All
significant steps in the infectious
disease testing process; (2) all
significant steps in obtaining, reviewing,
and assessing the relevant medical
records of the donor; (3) designating and
identifying quarantined tissue; and (4)
for prevention of infectious disease
contamination or cross-contamination
by tissue during processing. Sections
1270.31(a) and (b) also require recording
and justification of any deviation from
the written procedures. Section
1270.33(a) (21 CFR 1270.33(a)) requires
records to be maintained concurrently
with the performance of each significant
step in the procedures of infectious
disease screening and testing of human
tissue donors. Section 1270.33(f)
requires records to be retained regarding
the determination of the suitability of
the donors and such records required
under § 1270.21 (21 CFR 1270.21).
Section 1270.33(h) requires all records
be retained at least 10 years beyond the
date of transplantation, distribution,
disposition, or expiration of the tissue,
whichever is the latest. Section 1270.35
(21 CFR 1270.35) requires specific
E:\FR\FM\04DEN1.SGM
04DEN1
Agencies
[Federal Register Volume 71, Number 232 (Monday, December 4, 2006)]
[Notices]
[Pages 70409-70410]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20476]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N-0472]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Substances Prohibited from Use in Animal Food or Feed;
Animal Proteins Prohibited in Ruminant Feed
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on extending OMB approval on the
existing recordkeeping requirements for this information collection,
regarding animal proteins prohibited in ruminant feed.
DATES: Submit written or electronic comments on the collection of
information by February 2, 2007.
ADDRESSES: Submit electronic comments on the collection of information
to: https://www.fda.gov/dockets/ecomments. Submit written comments on
the collection of information to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of the
Chief Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1472.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Substances Prohibited From Use in Animal Food or Feed; Animal Proteins
Prohibited in Ruminant Feed--21 CFR 589.2000(e)(1)(iv) (OMB Control
Number 0910-0339)--Extension
This information collection was established because epidemiological
evidence gathered in the United Kingdom suggested that bovine
spongiform encephalopathy (BSE), a progressively degenerative central
nervous system disease, is spread to ruminant animals by feeding
protein derived from ruminants infected with BSE. This regulation
places general requirements on persons that manufacture, blend,
process, and
[[Page 70410]]
distribute products that contain or may contain protein derived from
mammalian tissue, and feeds made from such products.
The respondents for this collection of information are
manufacturers and or distributors of products that contain or may
contain protein derived from mammalian tissues and feeds made from such
products.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Recordkeeping Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual
21 CFR Section Recordkeepers per Recordkeeping Records Hours per Record Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
589.2000 (e)(1)(iv) 400 1 400 14 5,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: November 28, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy
[FR Doc. E6-20476 Filed 12-01-06; 8:45 am]
BILLING CODE 4160-01-S